title: Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review.
abstract: The selective estrogen receptor modulator tamoxifen is used in the treatment of early and advanced breast cancer and in selected cases for breast cancer prevention in high-risk subjects. The cytochrome P450 enzyme system and flavin-containing monooxygenase are responsible for the extensive metabolism of tamoxifen into several phase I metabolites that vary in toxicity and potencies towards estrogen receptor (ER) alpha and ER beta. An extensive overview of publications on the determination of tamoxifen and its phase I metabolites in biological samples is presented. In these publications techniques were used such as capillary electrophoresis, liquid, gas and thin layer chromatography coupled with various detection techniques (mass spectrometry, ultraviolet or fluorescence detection, liquid scintillation counting and nuclear magnetic resonance spectroscopy). A trend is seen towards the use of liquid chromatography coupled to mass spectrometry (LC-MS). State-of-the-art LC-MS equipment allowed for identification of unknown metabolites and quantification of known metabolites reaching lower limit of quantification levels in the sub pg mL(-1) range. Although tamoxifen is also metabolized into phase II metabolites, the number of publications reporting on phase II metabolism of tamoxifen is scarce. Therefore the focus of this review is on phase I metabolites of tamoxifen. We conclude that in the past decades tamoxifen metabolism has been studied extensively and numerous metabolites have been identified. Assays have been developed for both the identification and quantification of tamoxifen and its metabolites in an array of biological samples. This review can be used as a resource for method transfer and development of analytical methods used to support pharmacokinetic and pharmacodynamic studies of tamoxifen and its phase I metabolites.
authors.affiliation: Department of Pharmacy & Pharmacology, Slotervaart Hospital, The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. Bas.Teunissen@slz.nl
authors.forename: S F
authors.initials: SF
authors.lastname: Teunissen
authors.forename: H
authors.initials: H
authors.lastname: Rosing
authors.forename: A H
authors.initials: AH
authors.lastname: Schinkel
authors.forename: J H M
authors.initials: JH
authors.lastname: Schellens
authors.forename: J H
authors.initials: JH
authors.lastname: Beijnen
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000517:prevention & control; D002623:Chemistry Techniques, Analytical / Q000379:methods*; D047628:Estrogen Receptor alpha / Q000097:blood* / Q000187:drug effects; D047629:Estrogen Receptor beta / Q000097:blood* / Q000187:drug effects; D006801:Humans; D050216:Metabolic Detoxication, Phase I; D050217:Metabolic Detoxication, Phase II; D015203:Reproducibility of Results; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000097:blood* / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D013629:Tamoxifen / Q000097:blood* / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen